

Paul R Fortin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5878644/paul-r-fortin-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158
papers

10,868
citations

47
h-index

102
g-index

172
ext. papers

12,924
ext. citations

5.6
avg, IF

5.29
L-index

#	Paper	IF	Citations
158	Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus.. <i>Lupus Science and Medicine</i> , 2022 , 9,	4.6	1
157	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1231-1235	4.7	10
156	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
155	Expectations and educational needs of rheumatologists, rheumatology fellows and patients in the field of precision medicine in Canada, a quantitative cross-sectional and descriptive study. <i>BMC Rheumatology</i> , 2021 , 5, 52	2.9	
154	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021 , 73, 1789-1795	4.7	2
153	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021 , 30, 1283-1288	2.6	2
152	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2293-2302	9.5	2
151	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. <i>Journal of Psychosomatic Research</i> , 2021 , 140, 110314	4.1	3
150	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021 , 48, 541-547	4.1	4
149	The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021 , 23, 29	5.7	9
148	Platelets release mitochondrial antigens in systemic lupus erythematosus. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	12
147	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	5
146	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020 ,	4.7	2
145	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2274-2286	15.4	8
144	Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). <i>Arthritis Research and Therapy</i> , 2020 , 22, 132	5.7	4
143	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1734-1740	9.5	7
142	Platelets Disseminate Extracellular Vesicles in Lymph in Rheumatoid Arthritis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 929-942	9.4	18

141	Predictors of unsuccessful hydroxychloroquine tapering and discontinuation: Can we personalize decision-making in systemic lupus treatment?. <i>Arthritis Care and Research</i> , 2020 ,	4.7	1
140	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020 , 72, 1800-1808	4.7	7
139	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020 , 72, 658-666	9.5	11
138	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 106, 102340	15.5	15
137	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 356-362	2.4	18
136	Development and Acceptability of a Patient Decision Aid for Pain Management in Juvenile Idiopathic Arthritis: The JIA Option Map. <i>Patient</i> , 2020 , 13, 719-728	3.7	3
135	IgG-aggregates rapidly upregulate FcγRI expression at the surface of human neutrophils in a FcγRII-dependent fashion: A crucial role for FcγRI in the generation of reactive oxygen species. <i>FASEB Journal</i> , 2020 , 34, 15208-15221	0.9	2
134	FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus. <i>Blood</i> , 2020 , 136, 2933-2945	2.2	8
133	Pilot study of anti-mitochondrial antibodies in antiphospholipid syndrome. <i>Lupus</i> , 2020 , 29, 1623-1629	2.6	1
132	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020 , 72, 67-77	9.5	18
131	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019 , 175, 32-36	8.2	12
130	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019 , 46, 492-500	4.1	7
129	Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA. <i>Frontiers in Immunology</i> , 2019 , 10, 1026	8.4	13
128	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 464-468	5.3	38
127	Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. <i>Scientific Reports</i> , 2019 , 9, 4530	4.9	17
126	Response to Middleton KR et als. Yoga and SLE. <i>Complementary Therapies in Medicine</i> , 2019 , 43, 311	3.5	
125	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 893-902	4.7	46
124	Enhanced myelopoiesis and aggravated arthritis in S100a8-deficient mice. <i>PLoS ONE</i> , 2019 , 14, e0221528	3.7	3

123	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2069-2080	15.4	4
122	Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019 , 46, 166-175	4.1	8
121	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1010-1012	2.4	4
120	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 281-289	9.5	31
119	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019 , 71, 134-141	4.7	23
118	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1646-1652	4.7	5
117	Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E1550-E1559	11.5	113
116	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 393-396	4.1	23
115	The non-haemostatic role of platelets in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 195-213	8.1	49
114	Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms. <i>PLoS ONE</i> , 2018 , 13, e0196117	3.7	25
113	Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada. <i>Journal of Rheumatology</i> , 2018 , 45, 1440-1447	4.1	10
112	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018 , 70, 1294-1302	4.7	13
111	Sharing Ongoing Care with Primary Care Physicians Opens Up Opportunity for Timelier and Earlier Care by Rheumatologists for Patients with New Inflammatory Polyarthritiis. <i>Journal of Rheumatology</i> , 2018 , 45, 266-273	4.1	1
110	Alpha2beta1 Integrin (VLA-2) Protects Activated Human Effector T Cells From Methotrexate-Induced Apoptosis. <i>Frontiers in Immunology</i> , 2018 , 9, 2269	8.4	2
109	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 1426-1439	4.1	33
108	Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus. <i>Arthritis Care and Research</i> , 2017 , 69, 124-132	4.7	13
107	Temporal trends in prevalence, incidence, and mortality for rheumatoid arthritis in Quebec, Canada: a population-based study. <i>Clinical Rheumatology</i> , 2017 , 36, 2667-2671	3.9	19
106	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017 , 8, 16021	17.4	171

105	A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). <i>PLoS ONE</i> , 2017 , 12, e0189840	3.7	12
104	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. <i>Rheumatology</i> , 2017 , 56, 581-588	3.9	11
103	Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. <i>Environmental Research</i> , 2016 , 146, 85-91	7.9	63
102	Development of the Lupus Interactive Navigator as an Empowering Web-Based eHealth Tool to Facilitate Lupus Management: Users Perspectives on Usability and Acceptability. <i>JMIR Research Protocols</i> , 2016 , 5, e44	2	9
101	The Longterm Effect of Early Intensive Treatment of Seniors with Rheumatoid Arthritis: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery. <i>Journal of Rheumatology</i> , 2016 , 43, 861-8	4.1	11
100	Distinct Subtypes of Microparticle-containing Immune Complexes Are Associated with Disease Activity, Damage, and Carotid Intima-media Thickness in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2016 , 43, 2019-2025	4.1	34
99	Calcinosis is associated with digital ischaemia in systemic sclerosis-a longitudinal study. <i>Rheumatology</i> , 2016 , 55, 2148-2155	3.9	39
98	A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 218	5.7	18
97	Interferon- γ induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , 2015 , 58, 100-10	15.5	29
96	Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. <i>Environmental Research</i> , 2015 , 140, 474-8	7.9	43
95	Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. <i>Arthritis Care and Research</i> , 2015 , 67, 128-35	4.7	31
94	Assessment of the educational impact of an information leaflet on the knowledge of complications in systemic sclerosis. <i>Joint Bone Spine</i> , 2015 , 82, 373-5	2.9	2
93	Évaluation de l'impact d'une brochure d'information sur la connaissance des complications dans la sclérodémie systémique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015 , 82, 342-343	0.1	
92	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1530-6	2.4	51
91	2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. <i>Arthritis Care and Research</i> , 2015 , 67, 582-7	4.7	51
90	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1706-13	2.4	250
89	Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015 , 17, 143	5.7	112
88	Unpacking Early Work Experiences of Young Adults With Rheumatic Disease: An Examination of Absenteeism, Job Disruptions, and Productivity Loss. <i>Arthritis Care and Research</i> , 2015 , 67, 1246-1254	4.7	33

87	Job Accommodations Availability and Utilization Among People With Lupus: An Examination of Workplace Activity Limitations and Work Context Factors. <i>Arthritis Care and Research</i> , 2015 , 67, 1536-44	4.7	9
86	Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. <i>Arthritis Research and Therapy</i> , 2015 , 17, 197	5.7	38
85	Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. <i>Rheumatology</i> , 2015 , 54, 449-57	3.9	28
84	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 138-42	2.4	83
83	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , 2014 , 41, 875-80	4.1	17
82	Work factors are associated with workplace activity limitations in systemic lupus erythematosus. <i>Rheumatology</i> , 2014 , 53, 2044-52	3.9	14
81	Systemic autoimmune rheumatic disease prevalence in Canada: updated analyses across 7 provinces. <i>Journal of Rheumatology</i> , 2014 , 41, 673-9	4.1	22
80	Transitioning to employment with a rheumatic disease: the role of independence, overprotection, and social support. <i>Journal of Rheumatology</i> , 2014 , 41, 2386-94	4.1	16
79	Rheumatoid arthritis prevalence in Quebec. <i>BMC Research Notes</i> , 2014 , 7, 937	2.3	21
78	Toward the development of a lupus interactive navigator to facilitate patients and their health care providers in the management of lupus: results of web-based surveys. <i>JMIR Research Protocols</i> , 2014 , 3, e65	2	1
77	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013 , 42, 130-5	15.5	194
76	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2887-97		65
75	The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2013 , 40, 831-41	4.1	79
74	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1308-14	2.4	65
73	Non-lymphoma hematological malignancies in systemic lupus erythematosus. <i>Oncology</i> , 2013 , 85, 235-40	6.6	24
72	A hot spot for systemic lupus erythematosus, but not for psoriatic arthritis, identified by spatial analysis suggests an interaction between ethnicity and place of residence. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1579-85		7
71	Systematic review of validation studies of the use of administrative data to identify serious infections. <i>Arthritis Care and Research</i> , 2013 , 65, 1343-57	4.7	49
70	Association of smoking with cutaneous manifestations in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2013 , 65, 1275-80	4.7	51

69	Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012 , 7, 757-64	6.9	35
68	Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 179-85	5.3	93
67	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2677-86		2688
66	Longitudinal evolution of risk of coronary heart disease in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 968-73	4.1	16
65	Prevalence and risk factors for liver biochemical abnormalities in Canadian patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 254-61	4.1	24
64	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1502-9	2.4	115
63	Ten-year absolute fracture risk and hip bone strength in Canadian women with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 1378-84	4.1	15
62	Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. <i>Kidney International</i> , 2011 , 79, 914-20	9.9	47
61	Infections in the lupus patient: perspectives on prevention. <i>Current Opinion in Rheumatology</i> , 2011 , 23, 358-65	5.3	53
60	Peripheral neuropathy in patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 203-11	5.3	94
59	Posterior reversible encephalopathy syndrome: an emerging disease manifestation in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 353-63	5.3	36
58	Association of autoantibodies to heat-shock protein 60 with arterial vascular events in patients with antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2416-24		8
57	Molecular markers of injury in kidney biopsy specimens of patients with lupus nephritis. <i>Journal of Molecular Diagnostics</i> , 2011 , 13, 143-51	5.1	21
56	Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. <i>Journal of Rheumatology</i> , 2011 , 38, 658-66	4.1	27
55	Alterations in circulating fatty acid composition in patients with systemic lupus erythematosus: a pilot study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2011 , 35, 198-208	4.2	19
54	Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity. <i>Journal of Rheumatology</i> , 2011 , 38, 868-73	4.1	24
53	Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2011 , 38, 642-51	4.1	23
52	Thrombovascular events affect quality of life in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2011 , 38, 1017-9	4.1	12

51	Medication use in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2011 , 38, 271-4	4.1	10
50	Glomerular filtration rate predicts arterial events in women with systemic lupus erythematosus. <i>Rheumatology</i> , 2011 , 50, 799-805	3.9	8
49	Clinical and serologic factors associated with lupus pleuritis. <i>Journal of Rheumatology</i> , 2010 , 37, 747-53	4.1	23
48	Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. <i>Rheumatology</i> , 2010 , 49, 2172-80	3.9	109
47	Altered expression of TNF-alpha signaling pathway proteins in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 1658-66	4.1	25
46	The use of micronutrient supplements is not associated with better quality of life and disease activity in Canadian patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 87-90	4.1	9
45	Serum albumin as a marker for disease activity in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 1667-72	4.1	29
44	Development and initial validation of a self-assessed lupus organ damage instrument. <i>Arthritis Care and Research</i> , 2010 , 62, 559-68	4.7	33
43	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010 , 62, 863-8		203
42	The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. <i>Journal of Rheumatology</i> , 2009 , 36, 1200-8	4.1	92
41	Methodologic issues in the validation of putative biomarkers and surrogate endpoints in treatment evaluation for systemic lupus erythematosus. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2009 , 9, 108-12	2.2	9
40	Work disability in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009 , 61, 378-85		56
39	Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. <i>Nature Genetics</i> , 2009 , 41, 71-6	36.3	388
38	Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 100-107	7	22
37	Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. <i>Nature Genetics</i> , 2008 , 40, 1059-61	36.3	459
36	Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity. <i>Arthritis Research and Therapy</i> , 2008 , 10, R108	5.7	34
35	Patients with systemic autoimmune diseases could not distinguish comorbidities from their index disease. <i>Journal of Clinical Epidemiology</i> , 2008 , 61, 654-62	5.7	8
34	Expanded population of activated antigen-engaged cells within the naive B cell compartment of patients with systemic lupus erythematosus. <i>Journal of Immunology</i> , 2008 , 180, 1276-84	5.3	49

33	Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?. <i>Arthritis and Rheumatism</i> , 2008 , 59, 169-75		76
32	Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1796-804		107
31	The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. <i>Arthritis and Rheumatism</i> , 2007 , 57, 64-70		51
30	Costs of rheumatoid arthritis: new estimates from the human capital method and comparison to the willingness-to-pay method. <i>Medical Decision Making</i> , 2007 , 27, 138-50	2.5	43
29	Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1270-8		35
28	Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2211-9		21
27	"What do you expect? You're just getting older": A comparison of perceived osteoarthritis-related and aging-related health experiences in middle- and older-age adults. <i>Arthritis and Rheumatism</i> , 2006 , 55, 905-12		154
26	Role of radiation therapy in patients with a diagnosis of both systemic lupus erythematosus and cancer. <i>Arthritis and Rheumatism</i> , 2005 , 53, 67-72		27
25	Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005 , 53, 609-12		61
24	Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?. <i>Quality of Life Research</i> , 2005 , 14, 1333-44	3.7	69
23	Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. <i>Thrombosis and Haemostasis</i> , 2004 , 92, 1312-9	7	15
22	The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. <i>Journal of Rheumatology</i> , 2003 , 30, 2385-91	4.1	34
21	Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. <i>Thrombosis and Haemostasis</i> , 2003 , 90, 108-15	7	15
20	Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3327-30		306
19	Counterbalancing patient demands with evidence: results from a pan-Canadian randomized clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus. <i>Annals of Behavioral Medicine</i> , 2002 , 24, 88-99	4.5	42
18	Purpura fulminans and anticardiolipin antibodies in a patient with Grave's disease. <i>Scandinavian Journal of Rheumatology</i> , 2002 , 31, 371-3	1.9	13
17	Measuring clinically important changes with patient-oriented questionnaires. <i>Medical Care</i> , 2002 , 40, 1145-51	3.1	72
16	Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. <i>Journal of Clinical Epidemiology</i> , 2002 , 55, 488-97	5.7	41

15	Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2331-7		911
14	The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1410-8		54
13	Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. <i>Lupus</i> , 1999 , 8, 660-70	2.6	35
12	Recruitment strategies in superiority trials in SLE: lessons from the study of methotrexate in lupus erythematosus (SMILE). <i>Lupus</i> , 1999 , 8, 606-11	2.6	11
11	The role of stress in functional disability among women with systemic lupus erythematosus: a prospective study. <i>Arthritis and Rheumatism</i> , 1999 , 12, 112-9		52
10	The needs of patients with arthritis: the patient's perspective. <i>Arthritis and Rheumatism</i> , 1999 , 12, 85-95		60
9	Outcomes of total hip and knee replacement: preoperative functional status predicts outcomes at six months after surgery. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1722-8		556
8	Quality of life in systemic lupus erythematosus patients during more and less active disease states: differential contributors to mental and physical health. <i>Arthritis and Rheumatism</i> , 1999 , 12, 401-10		52
7	Comprehensive radiographic evaluation of diffuse idiopathic skeletal hyperostosis: development and interrater reliability of a scoring system. <i>Seminars in Arthritis and Rheumatism</i> , 1998 , 28, 88-96	5.3	39
6	Psychosocial contributors to mental and physical health in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998 , 11, 23-31		80
5	A controlled study of diffuse idiopathic skeletal hyperostosis. Clinical features and functional status. <i>Medicine (United States)</i> , 1997 , 76, 104-17	1.8	119
4	Familial antiphospholipid syndrome and HLA-DRB gene associations. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1907-8		9
3	Vasculitides associated with malignancy. <i>Current Opinion in Rheumatology</i> , 1996 , 8, 30-3	5.3	58
2	Validation of a meta-analysis: the effects of fish oil in rheumatoid arthritis. <i>Journal of Clinical Epidemiology</i> , 1995 , 48, 1379-90	5.7	156
1	Fatal pulmonary venoocclusive disease secondary to a generalized venulopathy: a new syndrome presenting with facial swelling and pericardial tamponade. <i>Arthritis and Rheumatism</i> , 1991 , 34, 228-33		39